Redbiotec plans to close CHF 9m Series A round this year – CEO

15 May 2020

Redbiotec, the Swiss developer of a therapeutic vaccine for genital herpes, is planning to close a CHF 9m Series A round this year, CEO Christian Schaub told Mergermarket.

Redbiotec, the Swiss developer of a therapeutic vaccine for genital herpes, is planning to close a CHF 9m Series A round this year, CEO Christian Schaub told Mergermarket.

 

The Zurich-based company will use the proceeds to advance its genital herpes (HSV-2) immunotherapy program into Phase I/IIa clinical studies, he said. It is seeking VCs and family offices interested in an investment with a relatively short horizon, since the company is aiming to sell the asset to one of the world’s large vaccine manufacturers once Phase IIa data is ready in approximately three and a half years, he added. The HSV-2 program will likely be spun out into a separate unit in the next year and a half, before it enters clinical trials, he said.

 

Redbiotec is simultaneously looking for co-development partners as an alternate scenario for its HSV-2 program, aiming to license the asset in the preclinical stage or Phase I, Schaub said.

 

The company’s HSV-2 asset could be worth more than USD 200m if it shows positive Phase IIa data, Schaub said. He cited a high unmet medical need for effective HSV-2 treatment given that existing antiviral pills cannot fully control the disease. Approximately 500m people globally suffer from the disease, according to a company presentation.

 

The company has already seen interest from pharma companies in its HSV-2 immunotherapy program, and expects more companies to show interest once it has Phase I clinical data.

 

Redbiotec’s cash burn rate is approximately CHF 2m-CHF 3m annually, a spokesperson said via email. To date, the company has raised more than CHF 20m from investors including Swiss VC RedalpineZuercher Kantonalbank and a number of early stage VCs, family offices and private investors, Schaub said. That amount includes funding for the human cytomegalovirus business that Redbiotec spun off and sold to Pfizer in 2014. 

 

Vischer is Redbiotec’s legal advisor and the company is constantly evaluating additional external advisors, a spokesperson said by email.

 

Redbiotec has experienced a “small” slowdown in its research due to the coronavirus pandemic, Schaub said. The company has been developing a SARS-CoV-2 vaccine platform, which it aims to use for rapid response to future global outbreaks and vaccine needs, he said. He said it was too early to share specific details about the vaccine development plan.

 

The company initiated its HSV-2 program in 2015, aiming to create a therapeutic vaccine that would reduce the severity and viral shedding of a genital herpes infection. Redbiotec identified two vaccine candidates that showed effectiveness in animal models, including a 90% reduction in outbreak severity. The immunotherapies also have the potential to prevent infection in healthy populations, or as prophylactics, according to the presentation. 

 

Redbiotec had a “very strong competitor” in Genocea Biosciences, Schaub said. The US-based company had worked on a genital herpes immunotherapy “with a similar rationale” to Redbiotec, he said, until deciding to abandon it in 2017 and redirected its efforts on cancer vaccines.

For the last three years the company has also been working on BRISPR, a proprietary bacteria platform technology that enables RNA and protein delivery for cancer and gene therapies. The platform’s lead asset RONC1 against pancreatic cancer is being tested in animal models, he said. Redbiotec is aiming to sell the platform while the candidates are still in the pre-clinical phase in the next 18 months to pharmaceutical company with an oncology program, Schaub said.

Similar pre-clinical deals have had up-front payments ranging from the “high double-digit millions to beyond USD 100m”, as well as milestone payments and royalties on future revenues, he said, declining to share specific valuation figures for the asset.

Other companies working on bacteria-based platforms are US-based Synlogic and Swiss biotech T3 Pharmaceuticals, he said. T3 Pharmaceuticals last year closed a CHF 12m funding round from investors including the Boehringer Ingelheim Venture Fund.

The company is a spin out from ETH Zurich and was founded in 2006.

[formidable id=1]
<div class="frm_forms with_frm_style frm_style_formidable-style" id="frm_form_1_container" > <form enctype="multipart/form-data" method="post" class="frm-show-form frm_pro_form frm_ajax_submit " id="form_popup-form" > <div class="frm_form_fields "> <fieldset> <legend class="frm_screen_reader">MergerMarket Subscribe Popup Form</legend> <div class="frm_fields_container"> <input type="hidden" name="frm_action" value="create" /> <input type="hidden" name="form_id" value="1" /> <input type="hidden" name="frm_hide_fields_1" id="frm_hide_fields_1" value="" /> <input type="hidden" name="form_key" value="popup-form" /> <input type="hidden" name="item_meta[0]" value="" /> <input type="hidden" id="frm_submit_entry_1" name="frm_submit_entry_1" value="4a6599a9eb" /><input type="hidden" name="_wp_http_referer" value="/redbiotec-plans-close-chf-9m-series-round-year-ceo/" /><div id="frm_field_1_container" class="frm_form_field form-field frm_required_field frm_none_container frm_first frm_half"> <label for="field_qh4icy" id="field_qh4icy_label" class="frm_primary_label">First Name <span class="frm_required" aria-hidden="true">*</span> </label> <input type="text" id="field_qh4icy" name="item_meta[1]" value="" placeholder="Enter your first name" data-reqmsg="This field cannot be blank." aria-required="true" data-invmsg="Name is invalid" aria-invalid="false" /> </div> <div id="frm_field_2_container" class="frm_form_field form-field frm_required_field frm_none_container frm_half"> <label for="field_ocfup1" id="field_ocfup1_label" class="frm_primary_label">Last Name <span class="frm_required" aria-hidden="true">*</span> </label> <input type="text" id="field_ocfup1" name="item_meta[2]" value="" placeholder="Enter your last name" data-reqmsg="This field cannot be blank." aria-required="true" data-invmsg="Last is invalid" aria-invalid="false" /> </div> <div id="frm_field_3_container" class="frm_form_field form-field frm_required_field frm_none_container ion_email accepts_business_email"> <label for="field_29yf4d" id="field_29yf4d_label" class="frm_primary_label">Email <span class="frm_required" aria-hidden="true">*</span> </label> <input type="email" id="field_29yf4d" name="item_meta[3]" value="" placeholder="Enter your business email address" data-reqmsg="This field cannot be blank." aria-required="true" data-invmsg="Please enter a valid email address" aria-invalid="false" /> </div> <div id="frm_field_4_container" class="frm_form_field form-field frm_top_container ion_company frm_hidden"> <label for="field_e6lis6" id="field_e6lis6_label" class="frm_primary_label">Company <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_e6lis6" name="item_meta[4]" value="" data-invmsg="Subject is invalid" aria-invalid="false" /> </div> <div id="frm_field_6_container" class="frm_form_field form-field frm_top_container ion_country frm_hidden frm12 frm_first"> <label for="field_otmou" id="field_otmou_label" class="frm_primary_label">Country <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_otmou" name="item_meta[6]" value="" data-invmsg="Subject is invalid" aria-invalid="false" /> </div> <div id="frm_field_7_container" class="frm_form_field form-field frm_top_container ion_utm_source frm_hidden"> <label for="field_eljps" id="field_eljps_label" class="frm_primary_label">utm_source <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_eljps" name="item_meta[7]" value="" data-invmsg="Subject is invalid" aria-invalid="false" /> </div> <div id="frm_field_8_container" class="frm_form_field form-field frm_top_container ion_utm_medium frm_hidden"> <label for="field_a8lma" id="field_a8lma_label" class="frm_primary_label">utm_medium <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_a8lma" name="item_meta[8]" value="" data-invmsg="Subject is invalid" aria-invalid="false" /> </div> <div id="frm_field_9_container" class="frm_form_field form-field frm_top_container ion_utm_campaign frm_hidden"> <label for="field_ommom" id="field_ommom_label" class="frm_primary_label">utm_campaign <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_ommom" name="item_meta[9]" value="" data-invmsg="Subject is invalid" aria-invalid="false" /> </div> <div id="frm_field_10_container" class="frm_form_field form-field frm_top_container ion_utm_content frm_hidden"> <label for="field_6kbqu" id="field_6kbqu_label" class="frm_primary_label">utm_content <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_6kbqu" name="item_meta[10]" value="" data-invmsg="Subject is invalid" aria-invalid="false" /> </div> <div id="frm_field_11_container" class="frm_form_field form-field frm_top_container ion_page_title frm_hidden"> <label for="field_fpzuk" id="field_fpzuk_label" class="frm_primary_label">Page Title <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_fpzuk" name="item_meta[11]" value="" data-invmsg="Subject is invalid" aria-invalid="false" /> </div> <div id="frm_field_12_container" class="frm_form_field form-field frm_top_container ion_page_url frm_hidden"> <label for="field_aj7hq" id="field_aj7hq_label" class="frm_primary_label">Page URL <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_aj7hq" name="item_meta[12]" value="" data-invmsg="Subject is invalid" aria-invalid="false" /> </div> <div id="frm_field_13_container" class="frm_form_field form-field frm_top_container ion_zerobouncestatus frm_hidden"> <label for="field_mrpjd" id="field_mrpjd_label" class="frm_primary_label">ZeroBounceStatus <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_mrpjd" name="item_meta[13]" value="" data-invmsg="Subject is invalid" aria-invalid="false" /> </div> <div id="frm_field_14_container" class="frm_form_field form-field frm_top_container frm_hidden ion_gftracklabel"> <label for="field_dqw7i" id="field_dqw7i_label" class="frm_primary_label">GFTrackEvent <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_dqw7i" name="item_meta[14]" value="" data-invmsg="Subject is invalid" aria-invalid="false" /> </div> <div id="frm_field_15_container" class="frm_form_field form-field frm_top_container ion_ip_address frm_hidden"> <label for="field_nzvgf" id="field_nzvgf_label" class="frm_primary_label">IP Address <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_nzvgf" name="item_meta[15]" value="185.191.171.22" data-frmval="185.191.171.22" data-invmsg="Text is invalid" aria-invalid="false" /> </div> <div id="frm_field_16_container" class="frm_form_field form-field frm_top_container frm_hidden ion_landing_page"> <label for="field_182c0" id="field_182c0_label" class="frm_primary_label">Landing Page <span class="frm_required" aria-hidden="true"></span> </label> <input type="text" id="field_182c0" name="item_meta[16]" value="" data-invmsg="Text is invalid" aria-invalid="false" /> </div> <input type="hidden" name="item_key" value="" /> <div class="frm_verify" aria-hidden="true"> <label for="frm_email_1"> If you are human, leave this field blank. </label> <input type="text" class="frm_verify" id="frm_email_1" name="frm_verify" value="" /> </div> <input name="frm_state" type="hidden" value="s8xfwaaizpBMz99drxmiKuSCMAW8OnK3kRg5FhimaDA=" /><div class="frm_submit"> <button class="frm_button_submit frm_final_submit" type="submit" formnovalidate="formnovalidate">Submit</button> </div></div> </fieldset> </div> </form> </div>